Glenmark Pharmaceuticals Inc., USA announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial in the US market on June 17, 2026. The product is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue® Injection, marketed by Provepharm SAS. This launch strengthens Glenmark's institutional portfolio in North America.

According to IQVIA sales data for the 12-month period ending April 2026, the market for ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), achieved annual sales of approximately $19.0 million. This figure includes sales of the brand and all available therapeutic equivalents. Glenmark's product is approved only for the indications listed in its approved label.

Market Context

The launch targets the institutional healthcare sector in the US. The following table outlines the key market metrics based on the provided data:

Marc Kikuchi, President & Business Head, North America, stated that the launch reflects the company's commitment to expanding access to quality, affordable medicines for healthcare institutions and patients. He added that this addition reinforces the focus on delivering reliable treatment options across the US market.

Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company with a presence in over 80 countries. The company operates 11 manufacturing facilities across four continents and six R&D centres.

Glenmark Pharmaceuticals Ltd has launched Winlevi (clascoterone 10 mg/g cream) across key European markets for the treatment of acne vulgaris. This launch marks the company's first introduction of a New Chemical Entity (NCE) in Europe, strengthening its dermatology portfolio. The product is authorized for adults and adolescents aged 12 to <18 years, with usage in adolescents limited to facial application. Glenmark Specialty S.A (GSSA), a wholly-owned subsidiary, is executing the launch through a mix of direct market entries and strategic partnerships.

Market Entry and Authorization

The European Commission granted marketing authorization to Cassiopea S.p.A., a subsidiary of Cosmo N.V., in October 2025. Glenmark has initiated direct launches in several markets, including the Nordics, Central and Eastern Europe, and Spain. In Portugal, the company has introduced the product through a strategic partner, with additional launches planned via partnerships across other European regions.

Product Details and Mechanism

Winlevi is the first topical acne therapy in more than 40 years with a first-in-class mechanism of action. Its active ingredient, clascoterone, acts as a topical androgen-receptor inhibitor locally in the sebaceous glands. This mechanism reduces sebum production and inflammation without systemic anti-androgen effects, supporting safe use in both males and females.

Strategic Significance

Jiri Havranek, Group Vice President & Business Head – Europe at Glenmark Pharmaceuticals, stated that the launch reflects the company's focus on bringing differentiated treatment options to patients. Giovanni Di Napoli, Chief Executive Officer of Cosmo, highlighted that the European launch supports the strategy of expanding the global reach of their innovative dermatology portfolio through trusted partnerships. The launch reinforces Glenmark's ability to execute multi-market launches in Europe through a combination of direct presence and strategic collaborations.